The emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receiving greater attention. Bacteriophage therapies are being revisited and present a promising opportunity to reduce the burden of bacterial infection in this post-antibiotic era. This review focuses on the current evidence supporting bacteriophage therapy against prevalent or emerging multi-drug resistant bacterial pathogens in respiratory medicine and the challenges ahead in preclinical data generation. Starting with efforts to improve delivery of bacteriophages to the lung surface, the current developments in animal models for relevant efficacy data on respiratory infections are discussed before finishing with a summary of findings from the select human trials performed to date.
Strain-level prediction of phage–host interactions (PHIs) is essential for developing targeted phage therapies. Traditional empirical and homology-based methods often lack the resolution and scalability needed for precision applications. Recently, a new generation of artificial intelligence-driven models has emerged leveraging genomic information to infer PHIs at strain-level resolution. Here, we review recent advances in strain-level PHI prediction, spanning biologically grounded feature-based models, hybrid representation-learning frameworks, phylogeny-agnostic machine learning approaches, and end-to-end deep learning architectures. We examine how these modelling strategies navigate shared structural constraints arising from sparse and imbalanced outcome data, assay-dependent labels, infection complexity, and limited generalization. We further analyse how evaluation design, negative definition, and train-test splitting strategies shape apparent strain-level performance, and why inappropriate benchmarking can inflate claims of biological resolution. Framing these issues in the context of clinical phage therapy, we examine how current strain-level PHI prediction frameworks perform under the biological, experimental, and data constraints characteristic of real-world therapeutic settings. Finally, we outline pragmatic pathways toward more robust, interpretable, and clinically translatable PHI prediction systems.
10 April 2025 in Microbiology Resource Announcements
We report the isolation of a bacteriophage with obligately lytic activity against Pseudomonas aeruginosa from wastewater. The reported phage, Minga-mokiny 4, appears to belong to the Schitoviridae family, is of the Litunavirus genus, and has a 72,362-bp genome. No known genes associated with lysogeny, bacterial resistance, or virulence were predicted.
/Summary: Pseudomonas aeruginosa is a priority pathogen in chronic and multidrug-resistant infections, yet therapeutic phages targeting this organism often exhibit variable and unpredictable efficacy. A mechanistic understanding of the genomic determinants governing phage–host interactions is therefore critical for the rational design of robust phage therapeutics. Here, we systematically dissected the genetic featrures underlying lytic outcomes across a diverse panel of P. aeruginosa -infecting phages. We comprehensively annotated receptor-binding proteins (RBPs), bacterial defence systems and phage-encoded anti-defence genes, and experimentally defined host receptor usage for each phage, linking receptor specificity to cognate RBPs. We identified multiple anti-defence systems—including vcrx089 , acrIIA24, atd1 , gnarl1 , klcA , darA and nmna (NARP2-associated)—and RBPs targeting lipopolysaccharide, type IV pili and flagella that are associated with enhanced lytic activity and represent tractable engineering targets. Across 174 genomic features analysed, 110 significantly influenced phage activity, with heterogeneous and context-dependent effects. Leveraging these features, we trained a machine-learning classifier that accurately predicted phage–host outcomes (AUC–ROC = 0.875), demonstrating that interaction phenotypes are encoded in definable genomic signatures. Together, our findings reveal the quantitative contribution of phage anti-defence systems to infectivity in P. aeruginosa and define a genomic framework for predicting and engineering lytic success. These results establish a foundation for the rational design of synthetic phages with enhanced host ranges.
Aims: This study aimed to characterize bacteriophages for potential therapeutic use against Staphylococcus aureus, focusing on clinical respiratory isolates of methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains. Specifically, it sought to evaluate phage lytic activity, host range, stability, biofilm disruption capabilities, and overall safety for therapeutic use. Methods and results: Novel phages, Koomba kaat 1 and Biyabeda mokiny 1, were identified and characterized using microbiological assays and bioinformatics. They exhibited lytic activity against clinical MSSA and MRSA isolates, disrupted biofilms from airway isolates, remained stable for at least one year in storage, and could be aerosolized without significant reductions in activity. Bioinformatic tools were used to assess safety, lifecycle, virulence, and prophage contamination when grown using their original isolation host. Receptor binding proteins within their genomes were also predicted, providing insight into their mechanisms of action. Both phages demonstrated strong efficacy against the clinical isolates tested and demonstrated robust stability under storage and delivery conditions. Conclusions: Koomba kaat 1 and Biyabeda mokiny 1 are promising candidates for phage therapy. Their efficacy against clinical S. aureus isolates, ability to break down biofilm, and stability for airway implementation, positions them as valuable tools for addressing persistent airway infections caused by S. aureus.
13 January 2026 in Microbiology Resource Announcements
Scedosporium species are filamentous fungi with inherent broad antifungal resistance that pose opportunistic infection threats. We present draft genome assemblies of S. aurantiacum (11 contigs) and S. apiospermum (9 contigs), derived from Oxford Nanopore sequencing of one Australian clinical isolate each.